Product Catalog

TesamorelinSpecifications & Batch COA

FDA-approved GHRH analogue for HIV-associated lipodystrophy. Reduces visceral fat and improves body composition.

KERUIHK-0206Tesamorelin product vial
Lyophilized PowderProduct image
Growth & Hormone

Tesamorelin

GMPKERUIHK-0206

FDA-approved GHRH analogue for HIV-associated lipodystrophy. Reduces visceral fat and improves body composition.

Product Specifications

CAS Number
218949-48-5
Catalog Purity
≥99.21%
Form
Lyophilized Powder
Catalog Grade
GMP
View batch documentation

Product Details

Tesamorelin specifications

Use the product name, catalog reference and available specifications below when discussing your requirements with our team.

Product
Tesamorelin
Catalog reference
KERUIHK-0206
CAS number
218949-48-5
Category
Growth & Hormone
Physical form
Lyophilized Powder

Latest reported batch: Tesamorelin

Batch PB-2026-TES-4311 · Oct 26, 2026

Sample specification
10 mg/vial
Reported appearance
White lyophilized powder
Reported molecular weight / identity
5135.80 Da
Analytical method
RP-HPLC (214/280 nm) / ESI-HRMS
Storage stated in this report
2–8°C, protect from light

Reported analytical results

Appearance
Conforms — White lyophilized powder; no visible particulates or cakingReport specification: White lyophilized powderMethod: Visual inspection
Reconstitution
<35 s; clear and colorless; no visible particlesReport specification: Clear solution after reconstitutionMethod: 2.0 mL BWFI; gentle swirling
HPLC Purity
99.52%Report specification: ≥99.0%Method: SOP-HPLC-TES-001-v3
Molecular Weight (MS)
5135.80 Da; +5.84 ppmReport specification: 5135.77 ± 0.50 DaMethod: SOP-MS-TES-002 / ESI-HRMS
Show 7 more test results
Amino Acid Analysis
ConformsReport specification: Conforms to Tesamorelin 44-aa sequenceMethod: AAA
Endotoxin (LAL)
< 0.15 EU/mgReport specification: < 1.0 EU/mgMethod: USP <85> gel-clot; reporting limit 0.05 EU/mg
Sterility (USP <71>)
No microbial growth observedReport specification: No evidence of microbial growthMethod: 14-day sterility test
Residual Solvents
Acetonitrile <100 ppm; Dichloromethane <50 ppm; DMF <100 ppmReport specification: ICH Q3C Class 2Method: GC-HS
Water Content (KF)
2.35%Report specification: ≤8.0%Method: Karl Fischer / USP <921>
Optical Rotation
−30.4°Report specification: −28° to −33°Method: 20°C; 1% acetic acid in water; c=0.5 g/100 mL
Peptide Content (AAA)
98.2%Report specification: ≥95.0%Method: AAA / nitrogen quantitation
Source COA: PB-2026-TES-4311-R20261026
Explore this category

Batch Documentation

Certificates of Analysis

Open a batch below to view its full report in our COA library, including available analytical attachments and PDF download.

PB-2026-TES-4311Report product: Tesamorelin · 10 mg/vialOct 26, 2026 · Reported purity: 99.52%View this batch COA
PB-2026-TES-4272Report product: TesamorelinOct 3, 2026 · Reported purity: 99.43%View this batch COA
PB-2026-TES-4272Report product: TesamorelinSep 01, 2026 · Reported purity: 99.4%View this batch COA
Show 3 earlier reports
PB-2026-TES-0224Report product: TesamorelinJul 29, 2026 · Reported purity: 99.4%View this batch COA
PB-2026-TES-0144Report product: TesamorelinApr 12, 2026 · Reported purity: 99.1%View this batch COA
PB-2025-TES-0108Report product: TesamorelinSep 17, 2025 · Reported purity: 99.2%View this batch COA

Product Inquiry

Request a Tesamorelin quotation

We synthesize any sequence at any scale — from milligram research quantities to multi-kilogram commercial batches. OEM, private label, and GMP manufacturing available. Response within 24 hours.

Discuss your requirements
Back to all products